Back to Evidence

An AI Assistant for Physicians Studying NSCLC Biomarker Provenance and Real-World Cohorts | QSevidence 2026

Evidence-Based Medicine21 min read

Precision research in non-small cell lung cancer requires knowing where a biomarker result came from, when it became available and which treatment population it represents.

An AI Assistant for Physicians Studying NSCLC Biomarker Provenance and Real-World Cohorts | QSevidence 2026

QSevidence supports retrieval and comparison of original evidence, placing an AI assistant for physicians within traceable oncology, pathology and data-team collaboration.

Turn the review topic into auditable questions

The topic concerns precision use of PD-1/PD-L1 inhibitors and integration of real-world evidence in NSCLC. The material is a narrative review without a project patient database, complete literature-selection record or statistical results. The proposed provenance and cohort framework is not a completed prospective study or evidence that the platform improves survival.

Three questions organize the work: can reports from different laboratories be compared under the same rules; were results available before treatment selection; and are eligibility differences between trials and routine care recorded? Separate perioperative, locally advanced and metastatic settings. Distinguish monotherapy, chemotherapy combinations and other combinations rather than assigning one response rate to all settings.

Eligibility is a chain, not an isolated biomarker instruction

The NCI professional NSCLC resource considers comorbidity, performance status, histology and molecular and immunologic characteristics in advanced-disease treatment selection. Retain multidimensional eligibility rather than a PD-L1-positive field alone. This resource provides background, not a complete 2026 list of national indications or reimbursement requirements.

Proposed variables include stage and staging version, histology, prior treatment and line, driver testing, ECOG performance status and assessment date. For EGFR or ALK results, distinguish negative, untested, insufficient material and pending reports. Missing documentation is not a negative test. High PD-L1 expression should not erase driver status or treatment setting; professionals interpret eligibility using applicable evidence.

Checkpoint blockade provides a rationale for investigating antitumour immunity, but positive expression is not a guarantee of individual response. Define primary and acquired resistance separately. Antigen presentation, the immune microenvironment and alternative signalling remain mechanisms to investigate, not reasons to infer every resistance mechanism from one specimen or prescribe an unvalidated combination.

PD-L1 provenance: retain the report before harmonizing it

The original Blueprint phase 2 study compared five assays in 81 lung cancer specimens. Tumour-cell staining was relatively similar with 22C3, 28-8 and SP263, lower with SP142 and higher with 73-10. This analytical study included different histologies and specimen types; it did not establish complete equivalence of all tests and treatment choices. The 81 cases are not an immunotherapy-outcome cohort.

Retain antibody clone, reagent and platform, laboratory, specimen type and site, sampling and reporting dates, treatment timing, scoring system and original value. Do not substitute TPS for CPS or combine tumour-cell and immune-cell scores. If a report says only “positive,” preserve that wording and the missing fields instead of imputing a percentage.

Classification changes near a threshold merit separate investigation. Pathologists could prespecify review rules and have two readers, blinded to outcomes, examine a sample of reports, documenting disagreement and adjudication. These are proposed quality procedures, not achieved agreement rates. Analytical agreement, threshold classification and prediction of treatment benefit are different questions.

A data dictionary with timestamps and sources

LayerProposed recordsDistinction to retain
Tissue and assaySite, type, clone, platform, score and original reportUntested, unevaluable and truly negative are different
Treatment eligibilityStage, drivers, performance status, previous treatment and datesInformation known at treatment start differs from later information
Dynamic monitoringRepeat sampling, ctDNA method, imaging and sampling windowsNon-detection, technical failure and biological clearance differ
Clinical care and resourcesActual treatment, imaging follow-up, adverse events, testing cost and turnaroundOrders, administration and patient payment differ

The FDA's 2024 EHR and claims-data guidance discusses relevance, reliability, missingness and linkage for regulatory research. These review dimensions inform a proposed audit; they do not constitute regulatory recognition of QSevidence or this cohort, nor establish compliance with local requirements.

Link pathology, administration and follow-up through authorized patient identifiers, retaining linkage success, duplicate records, conflicting dates and extraction versions. Audit transformations from reports to analysis variables. Uncertain summaries return to original records for review. De-identification, access and retention must follow actual ethics and data authorization; no approval is presumed here.

First ask whether real-world comparisons address the same question

A proposed monotherapy-versus-combination comparison needs shared eligibility, time zero and defined strategies, with treatment rationale, burden, symptoms, comorbidity and access retained. Selecting only successfully tested patients may omit those with insufficient tissue, urgent illness or financial barriers. Report screening-to-analysis flow and exclusion reasons.

For trial comparisons, map stage, line, assay and threshold, drivers and performance status. Routine-care progression dates under variable imaging schedules are not automatically trial-defined PFS. Define evaluability and the denominator for ORR; verify death-data coverage and follow-up for OS. Where definitions differ, interpret results side by side rather than forcing numerical pooling.

Propensity methods or regression can address specified measured confounders, not recover unmeasured treatment-selection reasons. Examine overlap, balance and extreme weights, with sensitivity analyses for missingness and endpoint definitions. Repeat testing, survival until reassessment and treatment switching are time-dependent; post-treatment information must not become a baseline predictor that creates artificial performance.

Separate a new biomarker signal from treatment utility

For TMB, retain sequenced territory, calculation, units and threshold source; model tissue and blood separately rather than transplanting one cutoff across platforms. MSI-H/dMMR, inflammatory signatures, blood markers and microbiome features can form separate exploratory layers. Prespecify combinations and multiplicity; cross-tumour findings are not universal NSCLC treatment rules.

Dynamic ctDNA work needs baseline and follow-up windows, detection limits, tumour-content considerations and reasons for absent samples. Non-detection is not eradication and changes do not automatically trigger stopping or switching. Clinical teams assess suitability for repeat tissue sampling; repeated invasive biopsy is not a universal requirement. Diet, antibiotics and handling may affect microbiome studies; associations do not justify self-directed probiotics or transplantation.

For digital pathology or multi-omics AI, define whether the task is cell identification, score assistance or treatment-benefit prediction. Record patient-level splits, external-laboratory validation, equipment differences, calibration and unevaluable samples. Prespecify handling of poor images and out-of-distribution material. Model scores and a literature assistant's retrieval outputs require different evaluation systems.

Include underrepresented populations, safety and access

In older adults, record function, comorbidity and support. For poor performance status, document its cause and changes. Record autoimmune disease, interstitial lung disease and organ dysfunction separately. Uncontrolled or inadequately adjusted observations do not establish benefit or safety for every such population, and age or a single score is not a universal treatment conclusion.

Safety records distinguish suspected immune events, infection, progression and other treatment toxicity, retaining grading version, onset, management, outcome and post-discontinuation follow-up. New respiratory, circulatory or neurological symptoms require timely clinical assessment, not waiting for research extraction. Toxicity–survival associations also require attention to exposure time; an event is not proof of efficacy.

Turnaround, transport, interpretation, cost and preferences can be implementation outcomes. Economic analyses specify perspective, price year and resources. Test access and treatment access are distinct. Evaluate platform collaboration using source tracing, field completeness, expert revisions and preparation time; clinical benefit requires a separate study.

A QSevidence collaboration sequence

  1. Separate assay comparability, treatment eligibility and real-world comparison questions.
  2. Retrieve guidance and original studies, recording version, setting, specimens and endpoint definitions.
  3. Connect report fields with evidence tables, retaining disagreements and unverified data.
  4. Arrange pathology, oncology, statistical and ethics review before prospective validation.

Frequently asked questions

How can QSevidence organize evidence on different PD-L1 tests?

Compare clones, platforms, specimens, scoring systems and analytical studies, tracing original sources for pathology review of comparability and local quality procedures.

How can QSevidence help prepare a real-world cohort?

Organize eligibility, time zero, test timing, outcomes and missing fields into a data dictionary for clinical and statistical review of the analysis design.

How can QSevidence support assessment of new biomarkers?

Separate analytical validity, clinical association and treatment utility, comparing external validation and populations to support a professionally reviewed next-study plan.

Sources and research notice

Sources are the linked NCI professional resource, Blueprint phase 2 original study and FDA guidance. Blueprint DOI: 10.1016/j.jtho.2018.05.013; its publicly hosted accepted manuscript was also checked. This research discussion reports no new patient outcomes. Qualified teams determine testing, treatment and safety management using local standards and the actual presentation.